1. Scrip
  2. >>New Products

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

 
• By Mandy Jackson

J&J subsidiary Janssen's Erleada (apalutamide) is the first therapy approved for non-metastatic castration-resistant prostate cancer (nmCRPC). The US FDA decision came about two months early, but the drug – priced at $10,920 per month, or $131,040 annually – may soon face competition.

ApproveOnKeyboard_1200x675

US FDA approval on Feb. 14 for Johnson & Johnson subsidiary Janssen Pharmaceutical Cos.'s Erleada (apalutamide) represents a lot of firsts, including the fact that the androgen receptor inhibitor's first indication makes it the first drug ever approved for non-metastatic castration-resistant prostate cancer (nmCRPC).

There are multiple approved treatments for metastatic CRPC – including Janssen's Zytiga (abiraterone), which may soon lose patent protection following a recent Patent Trial and Appeals Board (PTAB) decision –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip